Nothofagin suppresses mast cell-mediated allergic inflammation

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Mast cells are central to immunoglobulin E-mediated allergic inflammation, implicated in conditions such as asthma, atopic dermatitis, and allergic rhinitis.
• Nothofagin is a compound with demonstrated anti-inflammatory properties, previously shown to mitigate septic and vascular inflammation.

Purpose of the Study:

• To investigate the inhibitory effects of nothofagin on mast cell-mediated allergic inflammation.
• To evaluate the therapeutic potential of nothofagin in both in vitro and in vivo models of anaphylaxis.

Main Methods:

• Utilized cultured/isolated mast cells to assess nothofagin's impact on histamine and β-hexosaminidase release, calcium influx, pro-inflammatory cytokine gene expression, and signaling pathways (Lyn, Syk, Akt, NF-κB).
• Employed a passive cutaneous anaphylaxis mouse model to evaluate the in vivo efficacy of topically administered nothofagin, measuring local pigmentation and ear thickness.

Main Results:

• Nothofagin demonstrated a concentration-dependent inhibition of histamine and β-hexosaminidase release by reducing intracellular calcium levels.
• The compound suppressed the gene expression and secretion of key pro-inflammatory cytokines (TNF-α, IL-4) through downregulation of Lyn, Syk, Akt phosphorylation, and NF-κB nuclear translocation.
• In vivo studies confirmed that topical nothofagin application significantly reduced allergic reaction markers in a passive cutaneous anaphylaxis mouse model.

Conclusions:

• Nothofagin effectively inhibits mast cell activation and subsequent allergic inflammatory responses.
• These findings position nothofagin as a potential therapeutic agent for managing allergic inflammatory diseases driven by mast cell activity.